Condition
    Limited
    Effectiveness 4/5

    Rhodiola Rosea for Burnout

    Burnout is where rhodiola has its best evidence. Trials in stressed working populations show meaningful reductions in fatigue and mental exhaustion, often within the first week — unusually fast for a botanical.

    Overview

    Rhodiola rosea is the adaptogen with the most direct trial evidence in stress-related fatigue, which is the closest studied construct to burnout. A randomised trial of the standardised SHR-5 extract in people with stress-related fatigue found improvements in fatigue scores, attention and cortisol response over 28 days. An open-label trial in prolonged fatigue reported improvements across burnout-relevant domains, though without a placebo arm the effect size is unreliable.
    Burnout is an occupational syndrome, not a nutrient deficiency. The credible role for rhodiola is symptomatic support for exhaustion and reduced mental stamina while the underlying workload, recovery and boundary issues are addressed. A systematic review judged the evidence for physical and mental fatigue as promising but methodologically limited, which is why the verdict is likely rather than strong.

    How It Works

    The active constituents are rosavins and salidroside. Preclinical work shows modulation of the hypothalamic-pituitary-adrenal axis, with blunting of the exaggerated cortisol awakening response seen in chronic stress. Salidroside also inhibits monoamine oxidase, which raises availability of serotonin, dopamine and noradrenaline in the central nervous system.
    A second strand of mechanism concerns cellular energetics. Rhodiola extracts activate AMP-activated protein kinase and improve mitochondrial ATP production in muscle and neural tissue in animal work, which fits the reported reduction in physical fatigue. Rhodiola also attenuates stress-induced elevations in c-Jun N-terminal kinase signalling, a stress-response pathway implicated in fatigue and impaired cognition.

    Dosing & Protocol

    Trials in stress-related fatigue used 576 mg per day of SHR-5 extract, and other fatigue studies used 200 to 400 mg per day of extract standardised to 3 percent rosavins and 1 percent salidroside. Take it in the morning or early afternoon. Rhodiola is mildly stimulating, and evening doses commonly disrupt sleep, which is counterproductive in burnout.

    Burnout needs more than a supplement

    Persistent exhaustion warrants medical assessment to exclude anaemia, thyroid disease, sleep apnoea and depression, plus real changes to workload and recovery.

    Evidence

    Three linked sources support this pairing: a 2009 randomised, double-blind, placebo-controlled trial of SHR-5 extract in stress-related fatigue published in Planta Medica, a 2012 systematic review in BMC Complementary and Alternative Medicine covering physical and mental fatigue, and a 2017 open-label trial in prolonged or chronic fatigue symptoms. The systematic review found the trial evidence contradictory and of variable quality, which tempers the more positive individual results.

    Studies linked to this pairing.

    Rhodiola rosea in subjects with prolonged or chronic fatigue symptoms: results of an open-label clinical trial

    Score: 5/10
    2017
    observational
    n=100

    Lekomtseva Y, Zhukova I, Wacker A

    The fatigue symptoms continued to decline further, with statistically significant improvement at week 8.

    View source

    A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue

    Score: 7/10
    2009
    rct
    n=60

    Olsson EM, von Scheele B, Panossian AG

    Significant post-treatment improvements were observed for both groups (placebo effect) in Pines burnout scale, mental health (SF-36), and MADRS, with the SHR-5 group showing greater improvement in burnout and attention.

    View source

    Rhodiola rosea for physical and mental fatigue: a systematic review

    Score: 9/10
    2012
    systematic_review

    Ishaque S, Shamseer L, Bukutu C +1 more

    Two of six trials examining physical fatigue in healthy populations report R. rosea to be effective as did three of five RCTs evaluating R. rosea for mental fatigue.

    View source

    Safety

    Rhodiola is well tolerated in trials lasting up to three months, with adverse event rates close to placebo. The commonest complaints are dizziness, dry mouth and, when taken late in the day, difficulty sleeping. Caution is warranted in bipolar disorder, where its mild stimulant and monoamine effects have been linked in case reports to agitation or mood elevation. Safety in pregnancy and breastfeeding is not established.

    Take it before midday

    Rhodiola is mildly activating. Afternoon and evening doses frequently disrupt sleep, which worsens the fatigue you are trying to treat.

    Interactions & Conflicts

    The most important theoretical conflict is with serotonergic and monoamine-affecting medication. Salidroside inhibits monoamine oxidase, so combining rhodiola with SSRIs, MAO inhibitors or triptans should be discussed with a prescriber. In vitro work also suggests inhibition of CYP3A4 and P-glycoprotein, which could raise levels of drugs cleared by those routes, including some immunosuppressants and statins. Clinical significance is unconfirmed but worth flagging.
    Interacts withSeverityMechanismAction
    high
    		——
    moderate
    		——
    moderate
    		——
    moderate
    		——
    moderate
    		——

    References

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.